论文部分内容阅读
尿激酶(urokinase)是较链激酶毒性低的溶解血栓的药物,是唯一提纯的内源性纤溶酶。1957年ploug从尿中提纯,1958上Sokal试用于临床治疗血栓形成以来,20多年中对此疗法的价值及应用的方法尚属争论中。本文报告11例尿激酶治疗脑血栓形成,并探讨不同剂量和不同给药途径的效果。 1.诊断依据: 有脑血栓形成的典型临床症状,脑脊液无血性,全部病例均作脑血管造影证实,排除出血性中风者。
Urokinase is a thrombolytic drug that is less toxic than streptokinase and is the only purified endogenous plasmin. In 1957 ploug purified from the urine, 1958, Sokal trial for clinical treatment of thrombosis since the value of this therapy over 20 years and the method of application is still controversial. This article reports 11 cases of urokinase treatment of cerebral thrombosis, and explore different doses and different routes of administration. 1. Diagnosis based on: a typical clinical symptoms of cerebral thrombosis, cerebrospinal fluid no bloody, all cases were confirmed by cerebral angiography, excluding hemorrhagic stroke.